Cargando…

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Recent advances in targeted therapy and immunotherapy have substantially improved the treatment of melanoma. However, therapeutic strategies are still needed for unresponsive or treatment-relapsed patients with melanoma. To discover antibody–drug conjugate (ADC)–tractable cell surface targets for me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Jing, Jiao, Tao, Guo, Qian, Weng, Weining, Ma, Linjie, Zhang, Qing, Wang, Lijun, Zhang, Jianjian, Chen, Caiwei, Huang, Yaling, Wang, Mingqiao, Pan, Rong, Tang, Yanfang, Hu, Wenhao, Meng, Tao, Liu, Shu-Hui, Guo, Jun, Kong, Yan, Meng, Xun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Therapeutic Development and Chemical Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646479/ https://www.ncbi.nlm.nih.gov/pubmed/37668527 http://dx.doi.org/10.1158/0008-5472.CAN-23-1356

Ejemplares similares

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
por: Bei, Yuncheng, et al.
Publicado: (2023)

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
por: Boreddy, Srinivas Reddy, et al.
Publicado: (2023)

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
por: Kong, Chao, et al.
Publicado: (2023)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
por: Heuser, C, et al.
Publicado: (2003)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
por: Ludwig, Michael P., et al.
Publicado: (2023)

Impact of antibody framework residue V(H)-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme
por: Krauss, J, et al.
Publicado: (2004)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
por: Evans, Rachel J., et al.
Publicado: (2023)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection
por: Eser, Alexander, et al.
Publicado: (2020)

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
por: Groothuis, Patrick G., et al.
Publicado: (2023)

A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
por: Perez Bay, Andres E., et al.
Publicado: (2023)

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates
por: Heater, Natalie K., et al.
Publicado: (2023)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

Generation and validation of structurally defined antibody–siRNA conjugates
por: Nanna, Alex R, et al.
Publicado: (2020)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells
por: Moniaux, N, et al.
Publicado: (2007)

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
por: Qu, C F, et al.
Publicado: (2004)

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021)

Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach
por: De Simone, Clara, et al.
Publicado: (2022)

Application of an antibody chip for screening differentially expressed proteins during peach ripening and identification of a metabolon in the SAM cycle to generate a peach ethylene biosynthesis model
por: Zeng, Wenfang, et al.
Publicado: (2020)

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
por: Wiedemeyer, Wolf R., et al.
Publicado: (2022)

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
por: Zammarchi, Francesca, et al.
Publicado: (2022)

TJP1, a Membrane-Expressed Protein, is a Potential Therapeutic and Prognostic Target for Lung Cancer
por: Pu, Junyi, et al.
Publicado: (2022)

Hemostasis and inflammation: two of a kind?
por: Verhamme, Peter, et al.
Publicado: (2009)

The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
por: Altman, Raul, et al.
Publicado: (2010)

Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs)
por: Malecova, Barbora, et al.
Publicado: (2023)

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
por: Lyon, Robert P., et al.
Publicado: (2023)

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
por: Hooper, Andrea T., et al.
Publicado: (2022)

Impact of linker-drug on ion exchange chromatography separation of antibody-drug conjugates
por: Zhang, Zhaorui, et al.
Publicado: (2019)

Functional Mimicry of an Anti‐idiotypic Antibody to Nominal Antigen on Cellular Response
por: Ma, Jie, et al.
Publicado: (2002)

An array of 60,000 antibodies for proteome-scale antibody generation and target discovery
por: Wang, Zhaohui, et al.
Publicado: (2020)

Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas
por: Picco, Gianfranco, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sh96atu37gu2416q143bm98dvs